1. |
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095-2128.
|
2. |
陈伟伟, 高润霖, 刘力生, 等. 《中国心血管病报告 2014》概要. 中国循环杂志, 2015(7): 617-622.
|
3. |
胡大一, 郭艺芳. 甘油三酯增高的血脂异常防治中国专家共识. 中国医学前沿杂志:电子版, 2011(05): 115-120.
|
4. |
中国成人血脂异常防治指南指导联合委员会. 中国成人血脂异常防治指南. 中华心血管病杂志, 2007, 35(5): 390-419.
|
5. |
王彬尧, 王长谦. 甘油三酯与冠心病的关系. 国外医学. 心血管疾病分册, 2000(2): 79-81.
|
6. |
李建薇, 田浩明. 餐后甘油三酯代谢障碍与冠心病. 国外医学: 内科学分册, 2001, 28(11): 461-463, 479.
|
7. |
Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem, 2008, 317(1/2): 197-204.
|
8. |
Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation, 2008, 118(7): 731-742.
|
9. |
Canouï-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc Dis, 2010, 30(3): 252-259.
|
10. |
Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J, 1986, 112(2): 432-437.
|
11. |
Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol, 1996, 77(14): 1179-1184.
|
12. |
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease Independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk, 1996, 3(2): 213-219.
|
13. |
Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004, 110(17): 2678-2686.
|
14. |
Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis, 2010, 210(1): 243-248.
|
15. |
Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation, 1998, 97(11): 1029-1036.
|
16. |
Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb, 1991, 11(1): 2-14.
|
17. |
Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009, 302(18): 1993-2000.
|
18. |
Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011, 123(20): 2292-2333.
|
19. |
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366(9493): 1267-1278.
|
20. |
Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol, 2009, 104(4): 459-463.
|
21. |
Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol, 2001, 87(5A): 2B-7B.
|
22. |
He Y, Lam TH, Li LS, et al. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol, 2004, 14(1): 1-7.
|
23. |
Werner C, Filmer A, Fritsch M, et al. Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. Clin Res Cardiol, 2014, 103(12): 984-997.
|
24. |
Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the baltimore coronary observational long-term study. J Am Coll Cardiol, 1998, 31(6): 1252-1257.
|
25. |
von Eynatten M, Hamann A, Twardella D, et al. Atherogenic dyslipidaemia but not total-and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J, 2008, 29(10): 1307-1315.
|
26. |
Yun KH, Shin IS, Rhee SJ, et al. Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med, 2009, 24(4): 330-336.
|
27. |
Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk, 2000, 7(5): 339-345.
|
28. |
Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol, 1993, 71(11): 909-915.
|
29. |
Goldbourt U, Brunner D, Behar S, et al. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J, 1998, 19(Suppl H): H42-H47.
|
30. |
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999, 341(6): 410-418.
|
31. |
Lisak M, Demarin V, Trkanjec Z, et al. Hypertriglyceridemia as a possible independent risk factor for stroke. Acta Clin Croat, 2013, 52(4): 458-463.
|
32. |
Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol, 2000, 86(12A): 23L-27L.
|
33. |
Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 2008, 51(7): 724-730.
|
34. |
赵水平. 《甘油三酯增高的血脂异常防治中国专家共识》解读. 内科理论与实践, 2011, 6(6): 408-411.
|
35. |
Driver SL, Martin SS, Gluckman TJ, et al. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol, 2016, 67(10): 1227-1234.
|
36. |
Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb, 1992, 12(11): 1336-1345.
|
37. |
Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ, 1996, 312(736): 935-939.
|
38. |
Braun D, Gramlich A, Brehme U, et al. Post-prandial lipaemia after a moderate fat challenge in normolipidaemic men with and without coronary artery disease. J Cardiovasc Risk, 1997, 4(2): 143-149.
|
39. |
Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007, 298(3): 299-308.
|
40. |
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008, 300(18): 2142-2152.
|
41. |
Rajkumar C, Simpson H, Jennings GL, et al. Postprandial silent ischaemia following a fatty meal in patients with recently diagnosed coronary artery disease. J Hum Hypertens, 2000, 14(6): 391-394.
|
42. |
Pineda J, Marín F, Marco P, et al. Premature coronary artery disease in young (age<45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol, 2009, 136(2): 222-225.
|
43. |
厉其昀. 高甘油三酯血症与早发冠心病的关系. 现代医药卫生, 2006, 22(7): 974-975.
|
44. |
杨金玲, 李广平. 青年急性心肌梗死临床特点与冠状动脉造影分析. 临床荟萃, 2014(9): 961-964.
|
45. |
Sabik JF, Blackstone EH, Gillinov AM, et al. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation, 2006, 114(1 Suppl): I454-I460.
|
46. |
Kasai T, Miyauchi K, Yanagisawa N, et al. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart, 2013, 99(1): 22-29.
|
47. |
Rami Helvaci M, Kaya H, Gundogdu M. Gender differences in patients with metabolic syndrome in coronary artery interventions. Med Glas (Zenica), 2013, 10(1): 75-80.
|
48. |
Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988, 4(Suppl A): 5A-10A.
|